Clinical Trial Detail

NCT ID NCT02967692
Title A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

Therapies

Dabrafenib + Spartalizumab + Trametinib

Dabrafenib + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST